International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

15th Annual Congress - Kyoto 2017

September 24-27, 2017 │ Kyoto, Japan
Kyoto 2017 Congress, Expansion and Evolution of TDM and CT
Plenary and Symposium Sessions

yyyy-mm-dd Type Link Title and Presenters

2017-9-24 IATDMCT-JSTDM Joint Symposium YouTube icon full color

Recollections: the 1st CJSTDM & the 1st ICTDM
Kazuhiko ‘Pico’ Tanaka

[+] View Bio

Keywords: TBA

 

Tanaka Kazuhiko headshotKazuhiko ‘Pico’ Tanaka
Professor Emeritus
Osaka University of Pharmaceutical Sciences Adviser, Kidney Center Shirasagi Hospital Japan

 

Prof. Kazuhiko Tanaka trained as a heart surgeon after completing his education at Graduate School of Medicine, Osaka University. He was employed as an intensivist when the Intensive Care Unit (ICU) was established at the Osaka University Hospital in 1973. He began his clinical studies to establish a standardized program for post-cardiac surgery management before he moved to the ICU at the National Cardiovascular Center in 1978. When drug concentration measurement became practical around 1982, he and others at the Lab and the Pharmacy Department began working on fundamental and clinical studies on the adequate use of pharmacology. This led to the First Congress of Japan Society for Therapeutic Drug Monitoring in 1984 as well as to the first International Congress of Therapeutic Drug Monitoring in 1988. Having engaged in the field at several institutions, mostly concentrating on fundamental and clinical studies on the adequate pharmacology, he retired from Osaka University of Pharmaceutical Sciences in 2012.


2017-9-24 IATDMCT-JSTDM Joint Symposium YouTube icon full color

Overview of Clinical Toxicology
Gwendolyn Appell McMillin

[+] View Bio

Keywords: Clinical toxicology, Drugs of abuse, Pharmacokinetics, Toxicokinetics

 

McMillin 150x200Gwendolyn A. McMillin, PhD
Medical Director, Toxicology
Medical Director, Pharmacogenetics

 

Dr. McMillin is a professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. Dr. McMillin is actively involved in professional associations such as the International Association of Therapeutic Drug Monitoring and Clinical Chemistry (IATDMCT), the American Association for Clinical Chemistry (AACC), and the College of American Pathologists (CAP). Her primary research interests include detection of neonatal drug exposures, testing for pain and addiction management, as well as clinical applications and implementation of pharmacogenomics.


2017-9-24 IATDMCT-JSTDM Joint Symposium YouTube icon full color Improving clinical outcome using TDM
Teun van Gelder
[+] View Bio

Keywords: Intervention, Evidence, Clinical Trial, Pharmacometrics,TDM

 

van gelder 150x200Teun van Gelder
Professor in Clinical Pharmacology
Erasmus Medical Center, Rotterdam, The Netherlands

 

Teun van Gelder is a Professor in Clinical Pharmacology, as well as an internist-nephrologist and clinical pharmacologist in the Department of Hospital Pharmacy and Department of Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands.

 

Professor van Gelder was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a postdoctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr Randall E Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during that time.

 

Professor van Gelder’s current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology (2010-2017) and is now the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.


2017-9-24 IATDMCT-JSTDM Joint Symposium YouTube icon full color

History of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Steven H. Y. Wong

[+] View Bio

Keywords: Global association for both TDM and Clinical Toxicology

 

Steve Wong pSteven H. Y. Wong
Ph.D. DABCC(TC), FAACC, FACs
Wake Forest University School of Medicine, Winston-Salem, NC, USA

 

Steven H. Wong, Ph.D., DABCC (TC), FACB, is Professor of Pathology with tenure, Director of Clinical Chemistry and Toxicology/Core Laboratory, Department of Pathology, Wake Forest School of Medicine. He is Co-Director of Clinical and Translational Mass Spectrometry Center. Dr. Wong’s current scientific and clinical interests encompass clinical and translational applications of omics biomarkers for enabling personalized medicine and personalized justice: pharmacogenomics, proteomics, metabolomics, and mass spectrometry for clinical chemistry., TDM with emphasis on immunosuppressant and pain management therapy with adjunct pharmacogenomics and metabolomics., and oral fluid proteome and metabolome for clinical and forensic toxicology/workplace testing. In addition to over 125 publications and 157 abstracts, he edited/co-edited four books including Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine.

 

Prior to joining Wake Forest, Dr. Wong was a Professor of Pathology, Director/Co-Director, Clinical Chemistry/Toxicology, TDM, Pharmacogenomics and Proteomics, Department of Pathology, Medical College of Wisconsin. He also served as the Toxicology Scientific Director at the Milwaukee County Medical Examiner’s Office. He was an Associate Professor, and Director, Drug Analysis Division of the Department of Laboratory Medicine, University of Connecticut School of Medicine., and Associate Professor of Pathology and Associate Director of Clinical Chemistry, Johns Hopkins University School of Medicine.

 

An active American Association for Clinical Chemistry (AACC) member since 1980, Dr. Wong was the 2014 AACC President. He is a member of NACB, and of four divisions: TDM-CT (Founding Chair), Proteomics (Past Chair), Molecular Pathology (Past Chair), and Mass Spectrometry and Separation Science (Founding member). Outside AACC, Dr. Wong is a member of the Drug Testing Advisory Board of Substance Abuse and Mental Health Services Administration/DHHS, and a member of the Antibody Committee of the National Cancer Institute/NIH, and the newly established Foundation of NIH - Cancer Steering Committee/Biomarkers Consortium Working Group on Proteomic Assay Harmonization. In 2016, as part of the NCI Cancer Moonshot, he was appointed as a member of the Applied Proteogenomics Organizational Learning and Outcomes Network (APOLLO)/Technology Working Group. IN 2017, he was appointed to the Pain Committee of Wake Forest School of Medicine. He was a reviewer for NIH Glue grants. He served on the American Board of Clinical Chemistry. He received the Young Investigator’s Award from the Association of Clinical Scientists., Seligson/Golden and the Samuel Natelson Awards of AACC., and the FDA–CDRH Certificate of Appreciation from the FDA/Stakeholder TDM Review Development Team. He was the founding President of the International Association for TDM and Clinical Toxicology. He is an editorial board member for Clinical Mass Spectrometry, Pharmacogenomics, Therapeutic Drug Monitoring, Annuals of Clinical & Laboratory Science, and a past board member for Clinical Chemistry and Laboratory Medicine and Journal of Analytical Toxicology.


2017-9-24 IATDMCT-JSTDM Joint Symposium YouTube icon full color

The role of the laboratory in optimizing anti-infective therapies in critically ill patients
Pierre Wallemacq

[+] View Bio

Keywords: antibiotics, antivirals, antimycotics, biomarkers to guide pharmacotherapy, pharmacokinetics

 

Wallemacq 150x200Pierre Wallemacq
PharmD, PhD, EuSpLM
Cliniques Universitaires St Luc, Université catholique de Louvain,Brussels, Belgium

 

Pr. Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology, and clinical pharmacokinetics-pharmacolgy in the schools of medicine, pharmacy and biomedical sciences. He supervised several PhD theses in the field of personalized medicine.

 

He is author or co-author of about 220 peer-reviewed manuscripts and 11 textbook chapters, and has presented at more than 200 conferences on invitation. Most of his work is dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas, including analytical methods (LC-MSMS etc…). He joined the Board of Directors of the Belgian Poison Centre in 1998. He received the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) Charles E Pippenger Award, in 2011, for outstanding contributions to Therapeutic Drug Monitoring. Pierre Wallemacq is the past-president of the Royal Belgian Society of Laboratory Medicine (RBSLM), and of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM) or Clinical Biochemistry (CLB). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. In 2012, he became full member of the Royal Belgian Academy of Medicine, and served from 2013-2015 as president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).

 

He is currently Director of the Medical Laboratories in the Cliniques universitaires St Luc, Brussels, integrating the activities of clinical chemistry, microbiology, haematology, human genetics and pathology.


2017-9-25 Award Lecture 1 YouTube icon full color

Irving Sunshine Award Lecture
Alain Verstraete

[+] View Bio

Keywords: Clinical toxicology, overdose, poisoning, history of toxicology

 

Verstraete 150x200Alain Verstraete
Senior Professor
Laboratorium Voor Llinische Biologie, Gent, Belgium

 

Alain Verstraete studied medicine at Ghent University, and specialised in Laboratory Medicine and in vitro Nuclear Medicine at Ghent University Hospital. Since 1987 he is responsible for the Toxicology Laboratory of Ghent University Hospital. Since 2002, he is a part-time professor at the Faculty of Medicine and Health sciences of Ghent University. He currently is part-time senior full professor.

 

His main research interests in the past 20 years have been driving under the influence of psychoactive substances and therapeutic drug monitoring of beta-lactam antibiotics in intensive care and cystic fibrosis patients. He was the co-ordinator for the laboratories in the Belgian Toxicology and Trauma Study (BTTS) and was scientific advisor to Belgian Secretary of State Jan Peeters for drafting the Belgian legislation on drugs and driving. He was president of the working group on alcohol, drugs, medicines and driving of Directorate General TREN (transport and energy) of the European Commission. He was the coordinator for the EU-funded Rosita (1999-2000) and Rosita-2 (2003-2005) studies on roadside drug testing and played an important role in different tasks of the EU-funded DRUID project (2006-2011).

 

He is active in several scientific societies: President of the Toxicological Society of Belgium and Luxembourg (2014-2017), board member of the SFTA (French association of analytical toxicologists; 2008-2018), since 1999 webmaster of the International Association for Therapeutic drug monitoring and clinical toxicology (IATDMCT) and founding member and board member (till 2009) of the European Workplace Drug Testing Society (EWDTS).

 

He received several scientific awards: 2002 TIAFT award for excellence, 2002 ICADTS Haddon Award, 2002 AACC outstanding speaker award, 2005 Grand Prix de la SFTA, 2017 Irving Sunshine award of the IATDMCT. He has published many research papers and his Hirsch index is currently 27. He is member of the editorial board of several journals.


2017-9-24 Joint Symposium YouTube icon full color

Liaison between IATDMCT and Members
Denise Anne McKeown

[+] View Bio

Keywords: IATDMCT, Communication, Members

 

Denise McKeownDenise Anne McKeown
Forensic Toxicologist
University of Glasgow, UK

 

Denise Anne McKeown is a Forensic Toxicologist from the University of Glasgow who has over 15 years experience working in the fields of Forensic and Clinical Toxicology. During this time she has pursued her interest in bioanalytics and the steps involved to achieve quality data. Denise specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds in a variety of biological and non-biological matrices. She is also a reporting Forensic Toxicologist. Denise has contributed to several peer-reviewed publications and book chapters, and has presented at national and international meetings. Denise is an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) – Currently Treasurer and Past Chair of the Communications Committee and Young Scientists Committee. Denise is also a member of the Royal Society of Chemistry (RSC), London Toxicology Group (LTG) and The International Association of Forensic Toxicologists (TIAFT).


2017-9-25 Biomarkers and TDM of Immunosuppressive Drugs YouTube icon full color

Biomarkers in Solid Organ Transplantation: Prospects and Challenges
Eberhard Wieland

[+] View Bio

Keywords: long term outcome, individualized immunosuppression, pharmacodynamics, analytical performance, clinical validation

 

EberhardEberhard Wieland
Professor of Clinical Chemistry and Laboratory Medicine
Medical Director
Synlab Medical Care Center in Leinfelden-Echterdingen, Germany

 

Dr. Wieland received his MD in Biochemistry from the University, Heidelberg in 1982. He held a postdoctoral position at the University of California, San Diego, USA between 1985 and 1987. From 1987 to 1993 he received his training at the Georg-August-University Goettingen, Germany. From 2003-2018 he was Medical Director of the Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany in 2003. Dr. Wieland is extraordinary professor at the Medical Faculty of the Eberhard-Karls-University in Tuebingen, Germany. He is Fellow (FEBLM/MB) and President of the UEMS European Board of Laboratory Medicine/Medical Biopathology and a registered European Specialist in Laboratory Medicine (EuSpLM). Dr. Wieland conducts research in pharmacokinetics and pharmacodynamics of immunosupressants. His current research interest is in biomarkers to complement TDM.


2017-9-25 Biomarkers and TDM of Immunosuppressive Drugs YouTube icon full color

Biomarkers and TDM of immunosuppressive drugs in kidney transplantation focus on pharmacogenetics
Laure Elens

[+] View Bio

Keywords: - Biomarkers to guide pharmacotherapy; Immunosuppressive Drugs; Pharmacogenomics; Pharmacokinetics; TDM

 

Laure ElensLaure Elens
Université Catholique de Louvain (UCL)
Brussels, Belgium

 

Prof Laure Elens started her path with a Biomedical sciences master degree obtained in 2006 at the Université Catholique de Louvain (UCLouvain) in Brussels, Belgium. She has been rapidely passionated by the faboulous world of precision medecine and, more particularly, by the complexity of the influence of genetic markers on drug pharmacokinetics. After having completed her master degree, she started a PhD program oriented towads Anti-HIV drug pharmacogenetics under the supervision of Prof Vincent Haufroid (vice-chair of the Pharmacogenetics committee). During her formation, she has been welcomed in the friendly IATDMCT community as her PhD jury was composed of VIP IATDMCT members; Prof Pierre Wallemacq (past president 2013-2015), Prof Dr Pierre Marquet (past president 2011-2013) and Prof Dr Teun van Gelder (current president). Following the obtention of her PhD in 2010, she extended her competences and broaden her research landscape by starting a post-doctoral formation in the Erasmus Medical Center (Rotterdam), in the Pharmacogenetic core lab of Prof Ron van Schaik (chair of the Pharmacogenetics committee). After 2 years, she went back at the UCLouvain to start a 3-year project as a post-doctoral research fellow. In 2013, at 28 years old, she has been titled as a Professor in Pharmacokinetics and Biostatistics at the Pharmacy and biomedical sciences Faculty (FASB) in the Louvain Drug Research Institute (LDRI) at UCLouvain where she is now heading the Integrated PharmacoMetrics, PharmacoGenetics and PharmacoKinetics group (PMGK). Exciting and promising Popupulation-based pharmacokinetic studies and other more fundamental projects are currently driven.


2017-9-25 Biomarkers and TDM of Immunosuppressive Drugs YouTube icon full color

Determinants of intra-graft tacrolimus concentrations in renal transplant recipients
Benedetta Sallustio

[+] View Bio

Keywords: tacrolimus, CYP3A5, P-glycoprotein, renal transplant, tissue concentrations

 

Benedetta SallustioBenedetta Sallustio
Principal Medical Scientist, Clinical Pharmacology
The Queen Elizabeth Hospital
Woodville South, Australia

 

Dr Sallustio is Principal Medical Scientist in the Department of Clinical Pharmacology at the Queen Elizabeth Hospital, where she manages the Therapeutic Drug Monitoring service. She is also an Affiliate Associate Professor in the Discipline of Pharmacology at Adelaide University, and has research interests in pharmacogenomics of renal transplantation, the clinical pharmacology of myocardial metabolic agents, and the role of UGTs in bioactivation of drugs. Dr Sallustio is a long-standing member of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, and currently serves as co-chair of its Therapeutic Drug Monitoring working group. She is also the secretary of the Special Drugs Working Party of the Australasian Association of Clinical Biochemists, and is co-chair of the Scientific Program Advisory Committee for the 2018 International Congress of Therapeutic Drug Monitoring and Clinical Toxicology.


2017-9-25 Biomarkers and TDM of Immunosuppressive Drugs YouTube icon full color

High intrapatient variability of tacrolimus exposure is associated with poorer outcomes after liver transplantation
Camille Tron

[+] View Bio

Keywords:

 

Camille Tron

Rennes University Hospital
Rennes, France

 


2017-9-25 TDM for multi-drug resistant organisms YouTube icon full color

Colistin: The PK, PD and TD Characteristics of this 'Old' Antibiotic Provide the Basis for TDM
Roger Nation

[+] View Bio

Keywords:

 

 

 


2017-9-25 TDM for multi-drug resistant organisms YouTube icon full color

Therapeutic Drug Monitoring of Beta-lactams
Menino Osbert Cotta

[+] View Bio

Keywords: beta-lactam, PK-PD targets, efficacy, toxicity

 

Menino Osbert Cotta
Clinical Pharmacist
The University of Queensland
Brisbane, Australia

 

Dr Menino Cotta is a clinical pharmacist and holds research positions at both the School of Pharmacy (Postdoctoral Research Fellow) and Faculty of Medicine (Associate Lecturer) at the University of Queensland. His main areas of research focus are in critical care medicine, infectious diseases and clinical pharmacy.

 

Having completed his PhD in 2016 in the area of antimicrobial stewardship, Dr Cotta has commenced a postdoctorate funded through a competitive fellowship granted by the University of Queensland (2017-19). His work will seek to optimise dosing of commonly used beta-lactam antibiotics in critically ill patients to maximise therapeutic efficacy and improve patient outcomes. As part of this fellowship, Dr Cotta will seek to gain necessary skills and expertise in developing and conducting clinical pharmacokinetic/pharmacodynamic studies. Dr Cotta currently supervises 4 PhD students.


2017-9-25 YS Joint Symposium 2017 YouTube icon full color

Pharmacokinetics and therapeutic drug monitoring of monoclonal antibodies for inflammatory bowel diseases
Sophie Berends

[+] View Bio

Keywords:

 

Sophie Berends
Amsterdam UMC, University of Amsterdam
Amsterdam, Netherlands

 

In 2015, Sophie Berends graduated from the Rijksuniversiteit Groningen, the Netherlands, as a pharmacist. Currently, she works as a PhD candidate at the Amsterdam UMC, University of Amsterdam. Her PhD is a novel collaboration between the Hospital pharmacy and the Gastroenterology department, under supervision of prof. Mathôt and prof. D’Haens. Her research focuses on pharmacokinetics and pharmacodynamics of monoclonal antibodies used in patient with inflammatory bowel disease. The aim is to optimize biological therapy for each individual patient, that is personalized medicine.


2017-9-25 YS Joint Symposium 2017 YouTube icon full color

Bench-to-bedside research for the dermatological side effects induced by multiple tyrosine kinase inhibitors
Kazuhiro Yamamoto

[+] View Bio

Keywords: Molecular-targeted drugs, hand-foot skin reaction, dermatitis, STAT3

 

Kazuhiro Yamamoto
Lead Pharmacist, Department of Pharmacy
Kobe University Hospital
Kobe Japan

 

Kazuhiro Yamamoto graduated in 2016 for the Doctor degree of Philosophy in Pharmaceutical Science and is currently working as the lead pharmacist in the Department of Pharmacy, Kobe University Hospital. He won the Best Presentation Award of The 24th Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences in 2014, the Young Scientist Award of the Japanese Society of Pharmaceutical Health Care and Sciences in 2016, and the 15th Award to dispatch to IATDMCT (Ebihara Prize) in 2017.


2017-9-25 YS Joint Symposium 2017 YouTube icon full color

Therapeutic Drug Monitoring of Antiretrovirals: Applications in Management and Prevention
Mark Marzinke

[+] View Bio

Keywords:

 

Mark Marzinke
Johns Hopkins University School of Medicine
Baltimore, USA

 


2017-9-26 Plenary Lecture 2 YouTube icon full color

Why Use TDM and Dashboards for Monoclonal Antibodies? The Promise of Individualized Therapy
Diane Renee Mould

[+] View Bio

Keywords: Monoclonal antibodies, Inflammatory Disease, Pharmacokinetics, Loss of Response, Dashboard

 

Diane Renee Mould
President of Projections Research Inc
Phoenixville, USA

 

Dr Mould obtained her bachelors degree at Stevens Institute of Technology in 1984 in Chemistry and Chemical Biology. She received her PhD in Pharmaceutics and Pharmaceutical Chemistry at The Ohio State University (OSU) in 1989. She spent 29 years as a pharmacokineticist in industry where she specialized in population pharmacokinetic / pharmacodynamic modeling and was an associate Research Professor at Georgetown University. She has conducted population PK/PD analyses of hematopoietic agents, monoclonal antibodies, anti-cancer and anti-viral agents, antipsychotic, cardiovascular, and sedative/hypnotic agents. Dr Mould is involved in clinical trial simulation and optimal study design in drug development. She was a member of the Scientific Advisory Group for PharSight, where she assisted in development of clinical trial simulation software.

 

Currently, Dr Mould is president of Projections Research Inc., a consulting company offering pharmacokinetic and pharmacometric services. She is also the founder of Baysient LLC, a company that develops systems to individualize doses of drugs that are difficult to manage. She has published 88 peer-reviewed articles, 18 book chapters, presented 105 posters, made 114 national and international presentations and presented 6 podium sessions on advanced modeling and simulation approaches. She is an adjunct professor at the University of Rhode Island (URI), OSU, and the University of Florida, and teaches an annual class on disease progression modeling at the National Institutes of Health. Dr Mould taught 9 courses (OSU, URI and SUNY Buffalo) on specialized aspects of population pharmacokinetic and dynamic modeling. She is a member of the editorial board for Journal of Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology and Therapeutics, and Clinical Pharmacology and Therapeutics Pharmacometrics and Systems Pharmacology. She is a Fellow of the American College of Clinical Pharmacology and of the American Association of Pharmaceutical Sciences.


2017-9-26 Award Lecture 2 YouTube icon full color

C.E. Pippenger Award Lecture
Christoph Hiemke

[+] View Bio

Keywords: Psychoactive Drugs, Standards of Practice in TDM, Reference Range, Antidepressants, Antipsychotics

 

Christoph Hiemke
Emeritus Professor
University Medical Center of the Johannes Gutenberg University
Mainz, Germany

 

Christoph Hiemke is emeritus Professor at the University Medical Center of the Johannes Gutenberg University of Mainz, Germany. From 1987 until 2013, he has been head of the Neurochemical Laboratory of the Department of Psychiatry and Psychotherapy and was responsible for TDM of psychoactive drugs, first for the local university hospital and later for multiple psychiatric hospitals in Germany (about 20,000 requests per year). Christoph Hiemke was graduated at the University of Bonn, Germany as biologist in 1972. In 1977, he received his PhD degree at the Department of Pharmacology and Toxicology at Bonn after having finished a thesis entitled “Gas chromatographic analyses of endogenous phenyl- and indolalkylamines in biological fluids of schizophrenic patients”. Subsequently, he worked for ten years in the Department of Physiological Chemistry at the University of Essen, Germany. His research was related to the neuroendocrine control of gonadotropic hormone release. In 1987, he was nominated Professor of Neurochemistry at the University of Mainz, a position that included TDM of psychotropic drugs, in 1987 for lithium and tricyclic antidepressant drugs. By introducing automated HPLC methods with column switching and on line sample clean-up, TDM was extended to multiple psychoactive drugs, antidepressants, antipsychotics, anxiolytics, antidementia drugs and antimanic drugs and finally also to drugs for the treatment of substance related disorders. Most of the TDM drugs were newly approved drugs for which it was claimed that these drugs can be applied for patient treatment without TDM. Using TDM revealed unexpected pharmacological properties of the psychoactive drugs, especially a marked pharmacokinetic interaction potential of many drugs. Moreover, it could be demonstrated that TDM is most helpful to improve the efficacy and safety of new psychoactive drugs. TDM related research was conducted in close cooperation with clinical colleagues. Researchers came from all over the world to Mainz to see and learn the practice of TDM in psychiatry. The most fruitful cooperation was that with the TDM task force of the Association of Neuropsychopharmaology (AGNP) founded in 1992 by Pierre Baumann. From 2005 until 2013, the TDM group was chaired by Christoph Hiemke. The interdisciplinary TDM group prepared and published in 2004 guidelines for TDM of neuropsychopharmacologic drugs. These guidelines were widely accepted as the standard for TDM in psychiatry by hospitals and laboratories. They were updated twice, in 2011 and once again in 2017 Hiemke et al.: Consensus Guidelines forTherapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018;51:9-62 (see: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-116492.pdf). Since more 30 years, Professor Hiemke is highly active in the field of TDM. The Web of Science identifies 566 articles with Christoph Hiemke as author or co-author, PubMed search actually indicates 333 publications in peer reviewed journals, and the search profile “hiemke” AND “therapeutic drug monitoring” identifies 129 articles. His research included studies on drug-drug interactions or on the clinical and economic usefulness of TDM. Positron emission tomography (PET) studies in cooperation with Gerd Gruender and Frank Roesch enabled in vivo evaluation of drug concentrations in blood and target structure occupancy. Christoph Hiemke is an active member of the IATDMCT since many years. In 2011, he was co-chair of Eberhard Wieland for organization of the IATDMCT congress 2011 at Stuttgart. TDM of psychoactive drugs has become Christoph Hiemke’s major task aiming to improve neuropsychopharmacotherapy and use TDM as an efficient und useful tool.


2017-9-27 Award Lecture 4 YouTube icon full color

Patsalos Prize Lecture
Michael Neely

[+] View Bio

Keywords: busulfan, TDM, Bayesian

 

neelyMichael Neely
Director, Laboratory of Applied Pharmacokinetics and Bioinformatics,The Saban Research Institute,
Acting Chief, Division of Infectious Diseases,Children's Hospital Los Angeles
Associate Professor and Clinical Scholar,Department of Pediatrics, Keck School of Medicine,University of Southern California

 

Dr. Neely is an Associate Professor of Pediatrics (Clinical Scholar) at the Keck School of Medicine of the University of Southern California. He is a Board-certified pediatric infectious disease specialist with more than 20 years of experience in patient care and research. He serves as the Chief of Infectious Diseases at the Children’s Hospital of Los Angeles (CHLA) and the director of the CHLA Laboratory of Applied Pharmacokinetics and Bioinformatics. His research and clinical focus is on creating pharmacometric models of drug behavior to optimize dosing and outcomes for the individual patient.

 

Dr. Neely received his medical degree from the University of California, Davis, and completed an internship and residency at Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland in Ohio. In 2002, he completed two fellowships in the Divisions of Pediatric Infectious Diseases and Pediatric Pharmacology, both also from the Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland. He lectures internationally and has published over 100 peer-reviewed publications and nine book chapters.